AstraZeneca announced the intention to reach a definitive agreement for the acquisition of the rights to Actavis’ branded respiratory business in the US and Canada. The deal shall reach $600 million on completion and includes low single-digit royalties above a certain revenue threshold.

AstraZeneca will own the development and commercial rights in the US and Canada to aclidinium bromide inhalation powder and to roflumilast, the only once-daily oral PDE4 inhibitor currently on the market for COPD.

AstraZeneca will also own development rights in the US and Canada for LAS40464, the combination of a fixed dose of aclidinium with formoterol long acting beta agonist in a dry powder inhaler, which has been already approved in the European Union.

The transaction strengthens AstraZeneca’s respiratory position globally and builds on the acquisition of Almirall’s respiratory portfolio in 2014.


Please enter your comment!
Please enter your name here